Blue Sparrow LLC’s AbbVie ABBV Stock Holding History

Blue Sparrow LLC’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$76M	Buy	349,500 +224,500	+180%	+$49.8M	1.3%	17
2025 Q4	$28.6M	Buy	+125,000	New	+$28.5M	0.54%	32

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Blue Sparrow LLC's ABBV Position: Q1 2026 in Review

Blue Sparrow LLC increased its AbbVie (ABBV) stake by 180% in Q1 2026, buying an estimated $49.8M and bringing the position to 349,500 shares worth $76M. The position accounts for 1.3% of the portfolio, ranked #17.

Blue Sparrow LLC first reported a position in ABBV in Q4 2025 and has held it in 2 quarters since. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Blue Sparrow LLC held 349,500 shares of AbbVie worth $76M as of Q1 2026.
Blue Sparrow LLC bought 224,500 AbbVie shares in Q1 2026, an estimated $49.8M.
AbbVie made up 1.3% of Blue Sparrow LLC's portfolio in Q1 2026, its #17 holding.
Blue Sparrow LLC first reported a position in AbbVie in Q4 2025 and has held it in 2 quarters since.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Blue Sparrow LLC's 13F filing for Q1 2026, filed 15 May 2026.